Large scale studies of MLV vector integration in human CD34 cells or MLV pseudotype infection of human cancer cell lines has revealed a remarkably selective process in which more than half of the integrations target less than 2% of the human genome [17,18]. The gene discussed is CD34; the disease is cancer.